The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
September 30, 2024
Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Iptacopan (Fabhalta) for Paroxysmal Nocturnal Hemoglobinuria (online only)
September 30, 2024 (Issue: 1712)
The FDA has approved the complement factor B
inhibitor iptacopan (Fabhalta – Novartis) for
treatment of paroxysmal nocturnal hemoglobinuria
(PNH) in adults. Iptacopan is the first oral drug to
be approved in the US for this indication....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.